GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS
Author(s): ,
Jochen Buechner
Affiliations:
Oslo University Hospital Rikshospitalet,Oslo,Norway
,
Stephan A. Grupp
Affiliations:
Department of Pediatrics,Perelman School of Medicine, University of Pennsylvania,Philadelphia,United States;Division of Oncology,Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia,Philadelphia,United States
,
Shannon L. Maude
Affiliations:
Department of Pediatrics,Perelman School of Medicine, University of Pennsylvania,Philadelphia,United States;Division of Oncology,Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia,Philadelphia,United States
,
Michael Boyer
Affiliations:
Department of Pediatrics and Internal Medicine,University of Utah,Salt Lake City,United States
,
Henrique Bittencourt
Affiliations:
Department of Pediatrics,Faculty of Medicine, University of Montreal,Montreal,Canada;Hematology Oncology Division,CHU Sainte-Justine,Montreal,Canada;Charles-Bruneau Cancer Center,CHU Sainte-Justine Research Center,Montreal,Canada
,
Theodore W. Laetsch
Affiliations:
Department of Pediatrics,The University of Texas Southwestern Medical Center,Dallas,United States;Pauline Allen Gill Center for Cancer and Blood Disorders,Children's Health,Dallas,United States
,
Peter Bader
Affiliations:
Division for Stem Cell Transplantation and Immunology,Hospital for Children and Adolescents, University Hospital Frankfurt,Frankfurt,Germany
,
Michael R. Verneris
Affiliations:
Adult and Pediatric Blood and Marrow Transplant Program,University of Minnesota,Minneapolis,United States
,
Heather Stefanski
Affiliations:
Adult and Pediatric Blood and Marrow Transplant Program,University of Minnesota,Minneapolis,United States
,
Gary Douglas Myers
Affiliations:
Children's Mercy Hospital and Clinics,Kansas City,United States
,
Muna Qayed
Affiliations:
Aflac Cancer and Blood Disorders Center,Emory University,Atlanta,United States
,
Michael A. Pulsipher
Affiliations:
Division of Hematology Oncology/Blood and Marrow Transplant,Children's Hospital Los Angeles, USC Keck School of Medicine,Los Angeles,United States
,
Barbara De Moerloose
Affiliations:
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation,Ghent University Hospital,Ghent,Belgium;Cancer Research Institute Ghent (CRIG),Ghent,Belgium
,
Hidefumi Hiramatsu
Affiliations:
Department of Pediatrics,Graduate School of Medicine Kyoto University,Kyoto,Japan
,
Krysta Schlis
Affiliations:
Department of Pediatrics,Stanford University School of Medicine,Stanford,United States
,
Kara Davis
Affiliations:
Lucile Packard Children's Hospital Stanford,Palo Alto,United States
,
Paul L. Martin
Affiliations:
Division of Pediatric Blood and Marrow Transplant,Duke University Medical Center,Durham,United States
,
Eneida Nemecek
Affiliations:
Oregon Health & Science University,Portland,United States
,
Christina Peters
Affiliations:
Stem Cell Transplantation Unit,St. Anna Children's Hospital,Vienna,Austria
,
Patricia Wood
Affiliations:
Novartis Pharmaceuticals Corporation,East Hanover,United States
,
Tetiana Taran
Affiliations:
Novartis Pharmaceuticals Corporation,East Hanover,United States
,
Karen Thudium Mueller
Affiliations:
Novartis Pharmaceuticals Corporation,East Hanover,United States
,
Yiyun Zhang
Affiliations:
Novartis Pharmaceuticals Corporation,East Hanover,United States
Susana Rives
Affiliations:
Hospital Sant Joan de Déu,Barcelona,Spain
(Abstract release date: May 18, 2017) EHA Learning Center. A. Grupp S. Jun 24, 2017; 181763
Stephan A. Grupp
Stephan A. Grupp

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: S476

Type: Oral Presentation

Presentation during EHA22: On Saturday, June 24, 2017 from 16:00 - 16:15

Location: Hall E

Background
The CD19-targeted chimeric antigen receptor (CAR) T-cell therapy CTL019, an investigational therapy that reprograms cytotoxic T cells to eliminate target cells, resulted in high response rates and a manageable safety profile in pediatric/young adult patients (pts) with R/R B-cell ALL in a single-center trial.

Aims
We report an updated interim analysis from the first multicenter global pivotal registration trial of a CAR T-cell therapy (ELIANA; NCT02435849) including data for 68 pts infused with CTL019, 50 of whom were followed for ≥6 mo.

Methods
This is a single-arm, open-label, multicenter, global, phase 2 study of CTL019 in pediatric/young adult pts with CD19+ R/R B-cell ALL with ≥5% bone marrow lymphoblasts by morphology. CTL019 was manufactured from leukapheresed autologous peripheral blood T cells at a centralized manufacturing facility. The primary endpoint was overall remission rate (complete remission [CR] + CR with incomplete blood count recovery [CRi]) within 3 mo. Secondary endpoints included duration of remission (DOR), overall survival, safety, and cellular kinetics.

Results

As of November 2016, 88 pts were enrolled. There were 7 (8%) manufacturing failures, 9 (10%) pts were not infused due to death or adverse events (AEs), and 4 pts (5%) were pending infusion at the time of data cutoff. Following lymphodepleting chemotherapy in most pts (fludarabine/cyclophosphamide [n=64]) or other [n=1]), 68 pts were infused with a single dose of CTL019 (median dose, 3.0×106 [range, 0.2-5.4×106] transduced CTL019 cells/kg), with a median study follow-up of 6.4 mo. Median age was 12 y (range, 3-23 y); 59% of pts had prior allogeneic stem cell transplant (alloSCT). Five infused patients had not reached 3 mo of follow-up; among 63 evaluable pts, 52 (83% [95% CI, 71%-91%]) achieved CR/CRi within 3 mo of CTL019 infusion, all of whom had minimal residual disease–negative marrow. The relapse-free probability at 6 mo after remission onset was 75% (95% CI, 57%-87%; median DOR not reached). The probability of survival was 89% (95% CI, 77%-94%) at 6 mo and 79% (95% CI, 63%-89%) at 12 mo. Seven pts (13% of responders) proceeded to alloSCT within 6 months while in remission. Cytokine release syndrome (CRS) was graded using the UPenn scale and managed using a protocol-specific algorithm; CRS occurred in 78% of pts (21% grade 3; 27% grade 4); no CRS-associated deaths occurred. 38% of pts received tocilizumab for treatment of CRS with or without other anti-cytokine therapy. Most common grade 3/4 nonhematologic AEs (>15%) other than CRS were hypotension (22%), hypoxia (18%), and increased aspartate aminotransferase (16%). The incidence of serious AEs within 8 weeks of infusion was 69%. 15% of pts experienced grade 3 neuropsychiatric AEs, with no grade 4 events and no cerebral edema reported. Grade 3/4 neutropenia with high (>38.3˚C) fever occurred in 60% of pts. 2 pts died within 30 days of infusion (ALL progression, n=1; cerebral hemorrhage, n=1), and 9 pts died >30 days after infusion (ALL relapse/progression, n=6; HHV-6 encephalitis, pneumonia, systemic mycosis, n=1 each). CTL019 expansion in vivo correlated with CRS severity, and persistence of CTL019 along with B-cell aplasia in peripheral blood was observed for ≥1 year in some responders.

Conclusion
The ELIANA study confirmed the efficacy of a single infusion of CTL019, without additional therapy, observed in a previous interim analysis and a prior single-center CTL019 trial. AEs were effectively and reproducibly managed globally by appropriately trained personnel at study sites.

Session topic: 2. Acute lymphoblastic leukemia - Clinical

Keyword(s): Acute lymphoblastic leukemia

Code of conduct/disclaimer available in General Terms & Conditions